Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.04 USD | -19.95% | +38.81% | -54.86% |
Financials (USD)
Sales 2024 * | 25.22M | Sales 2025 * | 32.65M | Capitalization | 4.5M |
---|---|---|---|---|---|
Net income 2024 * | -24M | Net income 2025 * | -9M | EV / Sales 2024 * | 0.18 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.14 x |
P/E ratio 2024 * |
-0.19
x | P/E ratio 2025 * |
-0.84
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.21% |
Latest transcript on Eiger BioPharmaceuticals, Inc.
1 day | -19.95% | ||
1 week | +38.81% | ||
Current month | -39.26% | ||
1 month | -45.62% | ||
3 months | -48.99% | ||
6 months | -59.79% | ||
Current year | -54.86% |
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Director of Finance/CFO | 58 | 23-04-12 | |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 18 M€ | +3.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 3.04 | -19.95% | 17,019 |
24-04-24 | 3.798 | -3.86% | 14,300 |
24-04-23 | 3.95 | -1.25% | 28,020 |
24-04-22 | 4 | +67.36% | 78,021 |
24-04-19 | 2.39 | +9.13% | 141,623 |
Delayed Quote OTC Markets, April 25, 2024 at 03:58 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.86% | 4.5M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+45.26% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- EIGR Stock